Beijing Defengrui Biotechnology Co. Ltd Report issue

For profit Phase 3
Founded: Beijing China (2019)

Organization Overview

First Clinical Trial
2019
NCT05360927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Defengrei Biotechnology Co.,Ltd | Beijing Defengrui Biotechnology Co. Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

bdb-001 (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1